References
- National Institute for Health and Clinical Excellence. Capecitabine for the treatment of advanced gastric cancer. NICE Technology Appraisal Guidance 2010
- Kang Y-K, Kang W-K, Shin D-B, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomized phase III noninferiorty trial. Ann Oncol 2009;20:666-73
- Hong Kong Cancer Registry at Hospital Authority. Stomach cancer in Hong Kong 2009
- Allum WH, Blazeby JM, Griffin SM, et al. Guidelines for the management of oesophageal and gastric cancer. Gut 2002;50 (SupplV):v1-v23
- Ajani JA. Evolving chemotherapy for advanced gastric cancer. Oncologist 2005;10 (suppl3):49-58
- MacKenzie M, Spithoff K, Jonker D, Gastrointestinal Cancer Disease Site Group. Systemic therapy for advanced gastric cancer: a clinical practice guideline. Curr Oncol 2011;18:202-9
- Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46
- Norman G, Soares M, Peura P, et al. Capecitabine for the treatment of advanced gastric cancer. Health Tech Ass 2010;14(Suppl2):11-17
- Cavanna L, Artioli F, Codignola C, et al. Oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic gastric cancer (MGC). Am J Clin Oncol 2006;29:371-5
- Princess Margaret Hospital. PMH Formulary 2011: Hospital Authority of Hong Kong
- National Health Service. Chemotherapy protocol – gastrointestinal (upper cancer): capecitabine, epirubicin and oxaliplatin (EOX). July 2011 (Version 1.1). http://www.avon.nhs.uk/aswcs-chemo/STCP/Upper%20GI/ASWCS11%G1001_EOXfinal.pdf [Accessed April 15 2012]
- The Government of the Hong Kong Special Administrative Region. Special supplement no. 4 to the Government of the Hong Kong Special Administrative Region Gazette. Supplement to Gazette 2003;13:7
- Census and Statistics Department at the Government of the Hong Kong Special Administrative Region. Women and men in Hong Kong Key Statistics 2011 edn. http://www.statistics.gov.hk/pub/B11303032011AN11B0100.pdf [Accessed April 1 2012]
- Transport Department at the Government of the Hong Kong Special Administrative Region. Taxi Fare Information 2011. http://www.td.gov.hk/en/transport_in_hong_kong/public_transport/taxi/taxi_fare_of_hong_kong/index.html [Accessed April 1 2012]
- Princess Margaret Hospital. PMH Chemotherapy Protocol. 2011: Hospital Authority of Hong Kong
- Ishitsuka H, Shimma N, Horii I. Discovery and development of novel anticancer drug capecitabine. Yakugaku Zasshi 1999;119:881-97
- Ishitsuka H. Capecitabine: preclinical pharmacology studies. Invest New Drugs 2000;18:343-54
- Gralla RJ. New agents, new treatment, and antiemetic therapy. Semin Oncol 2002:29(Suppl4):119-24
- O’Grady NP, Alexander M, Burns LA, et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention; 2011. http://www.cdc.gov/hicpac/pdf/guidelines/bsi-guidelines-2011.pdf [Accessed April 1 2012]
- GiulianiG, FalconeA, GarrisonL. Economic evaluation of the cost of treating advanced gastric cancer (AGC) with capecitabine/cisplatin (XP) vs 5-FU/cisplatin (FP) regimens in an Italian setting. J Clin Oncol 2007;25:15022
- Tse VC, Ng WT, Lee V, et al. Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision making on reimbursement. BMC Cancer 2011;11:288